Table 4.
Clinical trials using NK cell therapies for pediatric brain tumors.
| NCTID | Trial | Phase | Number enrolled | Inclusion criteria | Outcome | Ref |
|---|---|---|---|---|---|---|
| NCT02271711 | Expanded Natural Killer Cell Infusion in Treating Younger Patients With Recurrent/Refractory Brain Tumors | I | 12 (9 received therapy) | Age <21 years, recurrent/refractory medulloblastoma, AT/RT, or ependymoma | NK cell harvest, expansion, release, and safety of 112 intraventricular infusions of NK cells were achieved without dose-limiting toxicity. Eight patients had progressive disease and one showed stable disease. | 12 |
| NCT01875601 | NK White Blood Cells and Interleukin in Children and Young Adults with Advanced Solid Tumors | I | 16 | Ages 2–29 with refractory pediatric malignant solid tumors | Results not yet available | – |
| NCT02100891 | Phase II STIR Trial: Haploidentical Transplant and Donor Natural Killer cells for Solid Tumors (STIR) | II | 15 | All ages, solid tumors, and CNS tumors (high-risk malignant brain tumors that are recurrent/refractory) | Donor NK infusions were well-tolerated without cytokine release syndrome. Median follow-up was 1.3 years with 1 and 2 yr OS of 64% and 40% respectively for the entire cohort. Disease control rate at 6 mo was 72%. | 114 |
| NCT01213407 | Dendritic Cell Cancer Vaccine for High-Grade Glioma | II | 87 | Ages 3–70, Supratentorial glioblastoma at the time of diagnosis with a total, subtotal, or partial resection of more than 70% by MRI | Progression-free survival at 12 mo did not differ significantly between control and vaccine group. Median overall survival was similar with 564 days in the vaccine group and 568 in the control group. | 118 |
| NCT02130869 | A Pilot Study of Immunotherapy Including Haploidentical NK Cell Infusion Following CD133 + Positively Selected Autologous Hematopoietic Stem Cells in Children With High Risk Solid Tumors and Lymphomas | I | 8 | Age <22 years, Group C includes high-risk brain tumors | Results not yet available | - |
| NCT04214730 | Study of NK Combined with Chemotherapy for Advanced Solid Tumor | 60 | Ages 10–90, patients with treatment refractory advanced solid cancer that are non-operable | Study ongoing | - |